Related Experiment Video

Updated: Jul 16, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma

Susu Zhang1, Kathleen L Engel2, Assil Fahs3

  • 1Dana-Farber Cancer Institute Boston, MA United States.

Cancer Discovery
|July 14, 2026
PubMed

Insights

This study identifies CDK8 as a key vulnerability in alveolar rhabdomyosarcoma (aRMS), a pediatric cancer. Targeting CDK8 shows promise as a new therapeutic strategy by inducing tumor cell differentiation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Alveolar rhabdomyosarcoma (aRMS) is an aggressive pediatric cancer with limited treatment options.
  • Fusion-driven aRMS presents unique therapeutic challenges and necessitates novel drug targets.

Purpose of the Study:

  • To identify novel therapeutic vulnerabilities in aRMS using functional genomic data.
  • To investigate the role of CDK8 as a potential drug target in aRMS.

Main Methods:

  • Complex-based analysis of DepMap functional genomic data.
  • In vitro and in vivo studies involving CDK8 knockout and pharmacologic inhibition.
  • Genome-scale CRISPR-Cas9 drug modifier screens.
  • Identification of key transcription factors using molecular assays.

Main Results:

  • CDK8 was identified as a dependency in aRMS, with its inhibition impairing tumor growth and inducing differentiation.
  • Pharmacologic inhibition of CDK8 elicited more dynamic transcriptional changes than genetic knockout.
  • Maximal anti-tumor activity of CDK8 inhibitors requires the Mediator kinase module and SAGA complex.
  • SIX4 was identified as a transcription factor mediating CDK8 inhibitor effects on differentiation and proliferation.

Conclusions:

  • CDK8 inhibition represents a promising differentiation-inducing therapeutic strategy for aRMS.
  • Findings suggest a gain-of-function mechanism for CDK8 inhibitors in aRMS treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.